Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Osiris/Genzyme Anticipates Approval Of Stem Cell Therapy Prochymal By 2010

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Osiris begins the FDA submission process for its mesenchymal stem cell therapy Prochymal this quarter, making a late-2009 approval of the world's first stem cell therapy a possibility if the agency grants a six-month review, and a first-cycle approval
Advertisement

Related Content

Osiris Will Focus On Liver GvHD While Sorting Data From Failed Studies
Osiris Hiccup In COPD Barely Registers In Maturing Stem Cell Sector
Osiris/Genzyme Put Stem Cells On The Deal Map
FDA Extends Review Of orBec For Acute GI Graft-Versus-Host Disease

Topics

Advertisement
UsernamePublicRestriction

Register

PS004075

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel